Last reviewed · How we verify
Middle Dose
At a glance
| Generic name | Middle Dose |
|---|---|
| Also known as | NL005（ Middle Dose） |
| Sponsor | Beijing Northland Biotech. Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus (PHASE1)
- Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia (PHASE2)
- Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) (PHASE2)
- Impact of Ligament of Marshall Resection on Atrial Fibrillation Occurrence in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Controlled Trial (NA)
- A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy (PHASE2)
- Comparison of the Analgesic Efficacy of Chest Wall Blocks in Coronary Artery Bypass Surgery (NA)
- Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH (PHASE2, PHASE3)
- Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Middle Dose CI brief — competitive landscape report
- Middle Dose updates RSS · CI watch RSS
- Beijing Northland Biotech. Co., Ltd. portfolio CI